| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Lava Therapeutics B.V (NASDAQ: LVTX)
LVTX Technical Analysis
4
| As on 21st Oct 2025 LVTX SHARE Price closed @ 1.47 and we RECOMMEND Sell for LONG-TERM with Stoploss of 1.71 & Strong Sell for SHORT-TERM with Stoploss of 2.41 we also expect STOCK to react on Following IMPORTANT LEVELS. |
LVTXSHARE Price
| Open | 1.47 | Change | Price | % |
| High | 1.50 | 1 Day | -0.02 | -1.34 |
| Low | 1.45 | 1 Week | -0.08 | -5.16 |
| Close | 1.47 | 1 Month | -0.10 | -6.37 |
| Volume | 1189596 | 1 Year | -1.17 | -44.32 |
| 52 Week High 3.11 | 52 Week Low 0.91 | ||||
NASDAQ USA Most Active Stocks
| BYND | 3.62 | 146.26% |
| AMRS | 0.14 | 100.00% |
| WBA | 11.98 | 0.50% |
| NERV | 6.41 | 140.98% |
| NVDA | 181.16 | -0.81% |
| RANI | 2.85 | 26.67% |
| LMDX | 0.02 | 0.00% |
| BITF | 4.49 | -9.84% |
| PLUG | 3.12 | -8.24% |
| ADAP | 0.05 | -16.67% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| LVTX Daily Charts |
LVTX Intraday Charts |
Whats New @ Bazaartrend |
LVTX Free Analysis |
|
|
LVTX Important Levels Intraday
| RESISTANCE | 1.57 |
| RESISTANCE | 1.54 |
| RESISTANCE | 1.52 |
| RESISTANCE | 1.50 |
| SUPPORT | 1.44 |
| SUPPORT | 1.42 |
| SUPPORT | 1.40 |
| SUPPORT | 1.37 |
LVTX Forecast October 2025
| 4th UP Forecast | 3.4 |
| 3rd UP Forecast | 2.78 |
| 2nd UP Forecast | 2.4 |
| 1st UP Forecast | 2.02 |
| 1st DOWN Forecast | 0.93 |
| 2nd DOWN Forecast | 0.54 |
| 3rd DOWN Forecast | 0.16 |
| 4th DOWN Forecast | -0.46 |
LVTX Weekly Forecast
| 4th UP Forecast | 2.20 |
| 3rd UP Forecast | 1.97 |
| 2nd UP Forecast | 1.82 |
| 1st UP Forecast | 1.68 |
| 1st DOWN Forecast | 1.26 |
| 2nd DOWN Forecast | 1.12 |
| 3rd DOWN Forecast | 0.97 |
| 4th DOWN Forecast | 0.74 |
LVTX Forecast2025
| 4th UP Forecast | 6 |
| 3rd UP Forecast | 4.55 |
| 2nd UP Forecast | 3.65 |
| 1st UP Forecast | 2.75 |
| 1st DOWN Forecast | 0.19 |
| 2nd DOWN Forecast | -0.71 |
| 3rd DOWN Forecast | -1.61 |
| 4th DOWN Forecast | -3.06 |
Lava Therapeutics B.V ( NASDAQ USA Symbol : LVTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
LVTX Business Profile
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. Address: Yalelaan 60, Utrecht, Netherlands, 3584 CM
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service